IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf ProspectusBusiness Wire • 08/05/22
IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022Business Wire • 08/04/22
IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt FacilityBusiness Wire • 06/22/22
IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022Business Wire • 05/06/22
IMV's Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual MeetingBusiness Wire • 04/28/22
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual MeetingBusiness Wire • 04/08/22
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational ResultsBusiness Wire • 03/17/22
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022Business Wire • 03/10/22
IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022Business Wire • 03/09/22
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCLBusiness Wire • 01/12/22
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High CohortsBusiness Wire • 12/21/21